|Dr. Jennifer K. Simpson Ph.D., M.S.N., C.R.N.P.||Chief Exec. Officer, Pres and Director||589.35k||N/A||49|
|Ms. Barbra C. Keck MBA||Chief Financial Officer||306.03k||N/A||39|
|Mr. John Purpura||Global Head of Operations and Exec. VP||385.38k||N/A||56|
|Mr. Robin Wagge||Sr. VP of Rubenstein Associates||N/A||N/A||N/A|
|Mr. J. Chris Houchins||Sr. VP of Clinical and Medical Affairs||N/A||N/A||53|
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers. The company is developing melphalan hydrochloride for Injection for use with the Delcath hepatic delivery system to administer high-dose chemotherapy to the liver. It offers melphalan hydrochloride under the Delcath Hepatic CHEMOSAT Delivery System for Melphalan name in Europe. The company was founded in 1988 and is headquartered in New York, New York.
Delcath Systems, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.